![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
,**,**,3
* Fred Hutchinson Cancer Research Center,
University of Washington, and
** Center for Health Studies, Group Health Cooperative, Seattle, WA
3To whom correspondence should be addressed. E-mail: jlampe{at}fhcrc.org.
Insulin-like growth factors (IGF) are essential for normal growth and maintenance of lean muscle mass; however, high insulin-like growth factor-I (IGF-I) and low IGF binding protein-3 (IGFBP-3) levels are also associated with several cancers. To test the hypothesis that long-term soy isoflavone supplementation decreases circulating IGF-I concentrations, we conducted a controlled, parallel-arm, double-blind intervention study with 150 participants (85% men), 50–80 y old. Participants were randomly assigned to consume a soy beverage powder daily for 12 mo. The active treatment group (+ISO) received soy protein containing 83 mg isoflavones, whereas the comparison group (-ISO) received soy protein containing 3 mg isoflavones. Serum IGF-I and IGFBP-3 were measured by ELISA. Mean change in serum IGF-I concentrations was similar in the two groups (+1.4 nmol/L in +ISO, +1.2 nmol/L in -ISO; P = 0.74, 95% confidence interval -1.1, +1.5 nmol/L for the 0.21 nmol/L difference between groups), indicating no effect of the isoflavone intervention. Similarly, the changes in IGFBP-3 and the IGF-I/IGFBP-3 ratio were similar in both groups, again showing no effect of +ISO treatment. A 12 mo, 83 mg/d soy isoflavone intervention did not modulate serum IGF in an older, mostly male population.
KEY WORDS: • isoflavones • insulin-like growth factor (IGF) • randomized controlled trial
This article has been cited by other articles:
|
|
 |
|
  J.-R. Zhou, L. Li, and W. Pan Dietary soy and tea combinations for prevention of breast and prostate cancers by targeting metabolic syndrome elements in mice Am. J. Clinical Nutrition, September 1, 2007; 86(3): 882S - 888S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R J. Barnard Prostate cancer prevention by nutritional means to alleviate metabolic syndrome Am. J. Clinical Nutrition, September 1, 2007; 86(3): 889S - 893S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vrieling, M. A. Rookus, E. Kampman, J. M. G. Bonfrer, C. M. Korse, J. van Doorn, J. W. Lampe, A. Cats, B. J. M. Witteman, F. E. van Leeuwen, et al. Isolated Isoflavones Do Not Affect the Circulating Insulin-Like Growth Factor System in Men at Increased Colorectal Cancer Risk J. Nutr., February 1, 2007; 137(2): 379 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fanti, R. Asmis, T. J. Stephenson, B. P. Sawaya, and A. A. Franke Positive effect of dietary soy in ESRD patients with systemic inflammation--correlation between blood levels of the soy isoflavones and the acute-phase reactants Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2239 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F Adams, P. D Lampe, K. M Newton, J T. Ylvisaker, A. Feld, D. Myerson, S. S Emerson, E. White, J. D Potter, and J. W Lampe Soy protein containing isoflavones does not decrease colorectal epithelial cell proliferation in a randomized controlled trial Am. J. Clinical Nutrition, September 1, 2005; 82(3): 620 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Voskuil, A. Vrieling, L. J. van't Veer, E. Kampman, and M. A. Rookus The Insulin-like Growth Factor System in Cancer Prevention: Potential of Dietary Intervention Strategies Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 195 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Adams, C. Chen, K. M. Newton, J. D. Potter, and J. W. Lampe Soy Isoflavones Do Not Modulate Prostate-Specific Antigen Concentrations in Older Men in a Randomized Controlled Trial Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 644 - 648. [Abstract] [Full Text] [PDF]
|
|
